Table 2 Blood pressure reductions-comparison of treatment groups in patients with a 12 months follow-up
differences at 12 months vs. baseline | |||
|---|---|---|---|
AZL-M(n = 2 237)Δ value (95 % CI) | ACE-inhibitor(n = 845) Δ value (95 % CI) | p-value for the comparisonof differences vs. baseline | |
Raw (unadjusted) | |||
∆ SBP, mmHg | 25.9 (25.1–26.7) | 22.6 (21.3–23.8) | <0.0001 |
∆ DBP, mmHg | 13.0 (12.5–13.5) | 11.4 (10.6–12.2) | <0.001 |
∆ Mean BP, mmHg | 17.3 (16.7–17.8) | 15.1 (14.3–15.9) | <0.0001 |
∆ Pulse pressure, mmHg | 12.9 (12.2–13.6) | 11.1 (10.1–12.2) | <0.05 |
∆ Heart rate, bpm | 3.0 (2.6–3.5) | 2.9 (2.2–3.7) | 0.64 |
BP < 140/90 mmHg, % | 61.1 (59.0–63.1) | 56.4 (53.0–59.8) | <0.05 |
Model 1 (adjusted) | |||
∆ SBP, mmHg | 25.3 (24.7–25.8) | 24.1 (23.3–25.0) | <0.05 |
∆ DBP, mmHg | 12.7 (12.4–13.1) | 12.0 (11.5–12.5) | <0.05 |
∆ Mean BP, mmHg | 17.0 (16.6–17.2) | 16.0 (15.5–16.6) | <0.05 |
∆ Pulse pressure, mmHg | 12.5 (12.1–13.0) | 12.1 (11.4–12.9) | 0.39 |
∆ Heart rate, bpm | 3.1 (2.7–3.4) | 2.9 (2.4–3.4) | 0.57 |
BP < 140/90 mmHg, % | 61.4 (59.4–63.4) | 55.9 (52.5–59.2) | <0.01 |
Model 2 (adjusted) | |||
∆ SBP, mmHg | 25.3 (24.8–25.8) | 24.0 (23.1–24.8) | <0.01 |
∆ DBP, mmHg | 12.7 (12.4–13.1) | 12.0 (11.5–12.5) | <0.05 |
∆ Mean BP, mmHg | 17.0 (16.6–17.3) | 16.0 (15.4–16.5) | <0.01 |
∆ Pulse pressure, mmHg | 12.6 (12.1–13.0) | 12.0 (11.2–12.7) | 0.15 |
∆ Heart rate, bpm | 3.1 (2.7–3.4) | 2.8 (2.3–3.4) | 0.50 |
BP < 140/90 mmHg, % | 61.7 (59.6–63.7) | 55.5 (52.1–58.9) | <0.01 |